In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CompuGROUP stalls offer for iSoft:

This article was originally published in Clinica

Executive Summary

CompuGROUP (Koblenz, Germany) has announced it will not increase its offer for iSoft, a move which leaves Australian firm IBA Health as the frontrunner to buy the UK medical software supplier. IBA's offer of 69p per share trumped CompuGROUP's bid of 66p per share (see Clinica No 1270, p 13).

You may also be interested in...

US COVID-19 Fraud: After Facebook Posts, Regulators Don’t ‘Friend’ ChromaDex

ChromaDex is among latest targets of FDA/FTC joint warnings identifying claims on websites as well as in social media posts that render products unapproved and misbranded drugs indicated to prevent or treat COVID-19.

Precious Cargo: DHL Gears To Deliver COVID-19 Vaccines

A senior DHL executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world and the specific challenges and complexities involved. The company has prior experience with the “deep frozen” temperatures needed for some candidates.

US FDA Details Trials To Evaluate New Drugs' Potential Interactions With Heartburn Remedies

Draft guidance on testing investigational drugs for drug-drug interactions with ingredients used in antacids, histamine H2-receptor antagonists and proton pump inhibitors points to including labels warnings on the new drugs about their concomitant use with the heartburn remedies.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts